Corporate report

MHRA Real-World Evidence Scientific Dialogue Programme

A programme to help decision-making across the lifecycle of products, benefitting both regulatory and health technology assessment (HTA) evaluations.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 13 January 2025
• Last updated: 10 February 2025 — See all updates

Documents

MHRA Real-World Evidence Scientific Dialogue Programme

HTML

Expression of Interest for the MHRA Real-World Evidence Scientific Dialogue Programme pilot

MS Word Document, 91.9 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The MHRA’s data strategy sets out an ambition to promote data-driven innovation and early access to innovative products through real-world evidence (RWE) and proactive approaches to safety surveillance.

In support of this, the we are launching a pilot RWE Scientific Dialogue Programme during 2025. This initiative is designed to help innovators refine their evidence generation strategies while providing clear guidance on regulatory expectations.

Published 13 January 2025
Last updated 10 February 2025 + show all updates

1. 10 February 2025

   Changed to add download link to Expression of Interest for the MHRA Real-World Evidence Scientific Dialogue Programme pilot

2. 13 January 2025

   First published.